Home › Burkitt Lymphoma
Pag-aaral pangklinika para sa Burkitt Lymphoma na nagre-recruit sa U.S.
63 pag-aaral para sa Burkitt Lymphoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX21 pag-aaral
- Milwaukee, WI16 pag-aaral
- Philadelphia, PA16 pag-aaral
- New York City, NY14 pag-aaral
- Chicago, IL14 pag-aaral
- Cincinnati, OH12 pag-aaral
- Atlanta, GA12 pag-aaral
- Seattle, WA11 pag-aaral
- Boston, MA10 pag-aaral
- Durham, NC10 pag-aaral
- Aurora, CO10 pag-aaral
- Los Angeles, CA10 pag-aaral
- Kansas City, MO10 pag-aaral
- Washington, DC9 pag-aaral
- Minneapolis, MN9 pag-aaral
- Orange, CA9 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Buffalo, NY8 pag-aaral
- Portland, OR8 pag-aaral
- Columbus, OH8 pag-aaral
- San Francisco, CA8 pag-aaral
- Nashville, TN8 pag-aaral
- Baltimore, MD8 pag-aaral
- Ann Arbor, MI8 pag-aaral
- Tampa, FL7 pag-aaral
- Clifton, NJ7 pag-aaral
- Dallas, TX7 pag-aaral
- Providence, RI7 pag-aaral
- Salt Lake City, UT7 pag-aaral
- Grand Rapids, MI7 pag-aaral
- Cleveland, OH7 pag-aaral
- Richmond, VA7 pag-aaral
- Greenburgh, NY7 pag-aaral
- San Antonio, TX7 pag-aaral
- Oklahoma City, OK7 pag-aaral
- Birmingham, AL7 pag-aaral
- Jacksonville, FL7 pag-aaral
- The Bronx, NY6 pag-aaral
- Mountain View, CA6 pag-aaral
- New Haven, CT6 pag-aaral
Ayos sa estado
- Alabama7 pag-aaral
- Arizona7 pag-aaral
- Arkansas5 pag-aaral
- California20 pag-aaral
- Colorado13 pag-aaral
- Connecticut7 pag-aaral
- Delaware7 pag-aaral
- District of Columbia5 pag-aaral
- Florida15 pag-aaral
- Georgia12 pag-aaral
- Hawaii5 pag-aaral
- Idaho6 pag-aaral
- Illinois14 pag-aaral
- Indiana6 pag-aaral
- Iowa7 pag-aaral
- Kansas6 pag-aaral
- Kentucky5 pag-aaral
- Louisiana4 pag-aaral
- Maine4 pag-aaral
- Maryland11 pag-aaral
- Massachusetts10 pag-aaral
- Michigan10 pag-aaral
- Minnesota10 pag-aaral
- Mississippi4 pag-aaral
- Missouri8 pag-aaral
- Nebraska5 pag-aaral
- Nevada6 pag-aaral
- New Hampshire4 pag-aaral
- New Jersey8 pag-aaral
- New Mexico3 pag-aaral
- New York20 pag-aaral
- North Carolina13 pag-aaral
- North Dakota5 pag-aaral
- Ohio17 pag-aaral
- Oklahoma7 pag-aaral
- Oregon8 pag-aaral
- Pennsylvania18 pag-aaral
- Rhode Island7 pag-aaral
- South Carolina5 pag-aaral
- South Dakota5 pag-aaral
- Tennessee10 pag-aaral
- Texas24 pag-aaral
- Utah7 pag-aaral
- Vermont3 pag-aaral
- Virginia7 pag-aaral
- Washington11 pag-aaral
- West Virginia3 pag-aaral
- Wisconsin17 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 2
366 Days – 46 Years · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Nagre-recruitPhase 3
Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03150693Blinatumomab Consolidation in Real World
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Nagre-recruitPhase 1/2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Nagre-recruitPhase 2
365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Nagre-recruitPhase 3
Edad 1 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Nagre-recruitPhase 1
Edad 0 hanggang 18 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Nagre-recruitPhase 1/2
31 Days – 30 Years · Lahat ng kasarian · Na-update Set 14, 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Nagre-recruitPhase 2
Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Nagre-recruitPhase 2
Edad 15 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.